Literature DB >> 20665494

Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer.

Shivani S Shinde1, Michele R Forman, Henry M Kuerer, Kai Yan, Florentia Peintinger, Kelly K Hunt, Gabriel N Hortobagyi, Lajos Pusztai, W Fraser Symmans.   

Abstract

BACKGROUND: The combination of increased parity and shorter breastfeeding duration might increase the odds of the least differentiated triple-negative breast cancer (BC) phenotype, theoretically because an expanded progenitor cell population from each pregnancy would incompletely differentiate postpartum.
METHODS: Subjects consisted of a consecutive case series of 2473 women treated for invasive breast cancer between 2001 and 2006. Breast cancer phenotype (triple-negative BC, vs non-triple-negative BC) was compared with reproductive and demographic information. Odds ratios (OR) with 95% confidence intervals (CIs) for the association of breastfeeding duration (months per child) and parity with triple-negative BC were calculated after adjusting for ethnicity, age at menarche, family history, and age at diagnosis.
RESULTS: Compared with non-triple-negative BC, triple-negative BC was associated with shorter duration of breastfeeding per child (OR, 0.93; 95% CI, 0.90-0.97) and with higher parity (OR, 1.12; 95% CI, 1.06-1.20). By using multivariate logistic regression, triple-negative BC was independently associated with higher parity (OR, 2.76 [95% CI, 1.86-4.08] if ≥3 live births; OR, 1.89 [95% CI, 1.30-2.74] if ≤2 live births vs nulliparae), breastfeeding duration (OR, 0.55 [95% CI, 0.41-0.74] if >2 mo/child and OR, 0.58 [95% CI, 0.42-0.82] if ≤2 mo/child vs none), African American ethnicity (OR, 2.10; 95% CI, 1.52-2.92), and younger age at diagnosis (OR, 3.02 [95% CI, 2.03-4.47] if ≤40 years vs >60 years).
CONCLUSIONS: Among women with invasive breast cancer, higher parity and the absence or short duration of breastfeeding were independently associated with triple-negative BC. Any duration of breastfeeding was found to be associated with lower probability of triple-negative BC, and the odds of this phenotype decreased with increasing duration of breastfeeding.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20665494     DOI: 10.1002/cncr.25443

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

1.  Breast cancer subtypes and previously established genetic risk factors: a bayesian approach.

Authors:  Katie M O'Brien; Stephen R Cole; Lawrence S Engel; Jeannette T Bensen; Charles Poole; Amy H Herring; Robert C Millikan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-31       Impact factor: 4.254

Review 2.  Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.

Authors:  Abenaa M Brewster; Mariana Chavez-MacGregor; Powel Brown
Journal:  Lancet Oncol       Date:  2014-11-24       Impact factor: 41.316

3.  Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.

Authors:  Tess O'Meara; Anton Safonov; David Casadevall; Tao Qing; Andrea Silber; Brigid Killelea; Christos Hatzis; Lajos Pusztai
Journal:  Breast Cancer Res Treat       Date:  2019-02-06       Impact factor: 4.872

4.  Mediation analysis of racial disparities in triple-negative breast cancer incidence among postmenopausal women.

Authors:  Juhua Luo; Candyce H Kroenke; Michael Hendryx; Aladdin H Shadyab; Nianjun Liu; Xiwei Chen; Fengge Wang; Fridtjof Thomas; Nazmus Saquib; Lihong Qi; Ting-Yuan David Cheng; Rhonda Arthur; Jean Wactawski-Wende
Journal:  Breast Cancer Res Treat       Date:  2021-03-07       Impact factor: 4.872

Review 5.  How many etiological subtypes of breast cancer: two, three, four, or more?

Authors:  William F Anderson; Philip S Rosenberg; Aleix Prat; Charles M Perou; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2014-08-12       Impact factor: 13.506

6.  Triple-Negative Breast Cancer: Clinical and Histological Correlations.

Authors:  Zeinab Elsawaf; Hans-Peter Sinn
Journal:  Breast Care (Basel)       Date:  2011-08-26       Impact factor: 2.860

7.  Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients.

Authors:  Hadjer Gaceb; Farid Cherbal; Rabah Bakour; Abdelhalim Ould-Rouis; Hassen Mahfouf
Journal:  Pathol Oncol Res       Date:  2017-05-06       Impact factor: 3.201

8.  Reproductive factors, heterogeneity, and breast tumor subtypes in women of mexican descent.

Authors:  Maria Elena Martinez; Betsy C Wertheim; Loki Natarajan; Richard Schwab; Melissa Bondy; Adrian Daneri-Navarro; Maria Mercedes Meza-Montenegro; Luis Enrique Gutierrez-Millan; Abenaa Brewster; Ian K Komenaka; Patricia A Thompson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-08-15       Impact factor: 4.254

9.  Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age.

Authors:  Christopher I Li; Elisabeth F Beaber; Mei-Tzu Chen Tang; Peggy L Porter; Janet R Daling; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2012-12-09       Impact factor: 4.872

10.  Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics.

Authors:  Sibgat Choudhury; Vanessa Almendro; Vanessa F Merino; Zhenhua Wu; Reo Maruyama; Ying Su; Filipe C Martins; Mary Jo Fackler; Marina Bessarabova; Adam Kowalczyk; Thomas Conway; Bryan Beresford-Smith; Geoff Macintyre; Yu-Kang Cheng; Zoila Lopez-Bujanda; Antony Kaspi; Rong Hu; Judith Robens; Tatiana Nikolskaya; Vilde D Haakensen; Stuart J Schnitt; Pedram Argani; Gabrielle Ethington; Laura Panos; Michael Grant; Jason Clark; William Herlihy; S Joyce Lin; Grace Chew; Erik W Thompson; April Greene-Colozzi; Andrea L Richardson; Gedge D Rosson; Malcolm Pike; Judy E Garber; Yuri Nikolsky; Joanne L Blum; Alfred Au; E Shelley Hwang; Rulla M Tamimi; Franziska Michor; Izhak Haviv; X Shirley Liu; Saraswati Sukumar; Kornelia Polyak
Journal:  Cell Stem Cell       Date:  2013-06-13       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.